CNS
The human nervous system is divided into the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS, in turn, is divided into the brain and the spinal cord, which lie in the cranial cavity of the skull and the vertebral canal, respectively. The CNS and the PNS, acting in concert, integrate sensory information and control motor and cognitive functions. Based on its functions, the CNS can be divided into three main functional components: the sensory system, the motor system, and homeostatic and higher brain functions. Cell signaling throughout the CNS occurs by means of neurotransmitters or ions of various kinds interacting at membrane bound receptors and ion channels that, in turn, send the signal through second messenger systems to different compartments of the cell. Malfunctions of the CNS can cause numerous diseases and disorders such as Alzheimer's and Parkinson's disease, multiple sclerosis (MS), anxiety, schizophrenia, and many others. Although many of these failures of the CNS appear to be age related, some occur already in a very early stage of development of the organism, or may even be genetically inherited. The prevention and treatment of neurological disorders represents one of the most difficult and challenging goals of modern medical research.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
1714 | (R)-(+)-SLV 319 | Inactive enantiomer of SLV 319 | €95.00 | |
1235 | Abnormal cannabidiol | Cannabinoid agonist | €135.00 | |
1218 | AM 251 | CB1 antagonist | €95.00 | |
1219 | AM 281 | CB1 antagonist | €95.00 | |
2791 | AM 4113 | CB1 antagonist | €105.00 | |
2541 | APD 597 | Orally bioavailable selective GPR119 agonist | €125.00 | |
2380 | APD 668 | Potent and selective, orally active GPR119 agonist | €125.00 | |
1572 | AR 231453 | Cannabinoid GPR119 agonist | €80.00 | |
3430 | AS1269574 | Selective and orally available GPR119 agonist | €90.00 | |
1234 | Cannabidiol | GPR55 antagonist | €105.00 | |
3955 | CB2R PAM C2 | First synthetic, potent and orally active CB2 receptor PAM | €120.00 | |
2015 | CP 945598 | CB1 antagonist | €135.00 | |
2119 | CP 945598 hydrochloride | CB1 antagonist | €135.00 | |
3632 | Genistein | CB1 antagonist | €70.00 | |
1925 | GW 842166X | Cannabinoid CB2 receptor agonist | €110.00 | |
1440 | HU 308 | CB2 agonist | €140.00 | |
1574 | Iodopravadoline | CB2 antagonist | €75.00 | |
1418 | JWH 133 | CB2 agonist | €110.00 | |
2092 | MBX 2982 | Potent and selective GPR119 agonist | €125.00 | |
1550 | MK 0364 | CB1 antagonist/inverse agonist | €95.00 | |
3028 | ML184 | Potent and selective GPR55 agonist | €120.00 | |
4125 | ML193 | Highly potent and selective GPR55 antagonist | €90.00 | |
1211 | Palmitoylethanolamide | Endocannabinoid; GPR55 agonist | €75.00 | |
1712 | rac-(±)-SLV 319 | Racemate of CB1 antagonist Ibipinabant (Axon 1713) | €110.00 | |
1713 | SLV 319 | CB1 antagonist | €105.00 | |
1220 | SR 141716 hydrochloride | CB1 antagonist | €70.00 | |
1924 | SR 144528 | CB2 receptor antagonist and/or an inverse agonist | €95.00 | |
2543 | ZCZ 011 | Brain penetrant CB1 positive allosteric modulator (PAM) | €90.00 |